Literature DB >> 32027845

Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?

Sabine Schmid1, Martin Früh2, Solange Peters3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32027845     DOI： 10.1016/S1470-2045(19)30859-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

Review 1.  A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.

Authors:  Lorenzo Belluomini; Alessandra Dodi; Alberto Caldart; Dzenete Kadrija; Marco Sposito; Miriam Casali; Giulia Sartori; Miriam Grazia Ferrara; Alice Avancini; Emilio Bria; Jessica Menis; Michele Milella; Sara Pilotto
Journal:  Transl Lung Cancer Res       Date:  2021-07

2.  Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma.

Authors:  Hongjin Chen; Ruixue Xia; Long Jiang; Yong Zhou; Haojun Xu; Weiwei Peng; Chengyun Yao; Guoren Zhou; Yijie Zhang; Hongping Xia; Yongsheng Wang
Journal:  Front Oncol       Date:  2021-03-09       Impact factor: 6.244

3.  An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer.

Authors:  Yuexiao Qi; Xiaojun Xia; Lihua Shao; Liyun Guo; Yumei Dong; Jinhui Tian; Lijun Xu; Ruijun Niu; Shihong Wei
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

4.  Successful salvage therapy using high-dose furmonertinib (AST2818) for non-small-cell lung cancer after Osimertinib resistance: a case report.

Authors:  Daoan Cheng; Shuxian Tang; Dong Li; Weiqing Zhao; Wei Wei; Cheng Fang; Mei Ji
Journal:  Anticancer Drugs       Date:  2022-08-10       Impact factor: 2.389

5.  Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy.

Authors:  Yuhong Liu; Xiaoyong Dai; Shengwei Jiang; Mulan Qahar; Chunyan Feng; Dongdong Guo; Lijun Wang; Shaohua Ma; Laiqiang Huang
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

Review 6.  Non-small-cell lung cancer: how to manage EGFR-mutated disease.

Authors:  Federica Pecci; Luca Cantini; Giulio Metro; Biagio Ricciuti; Giuseppe Lamberti; Ammad Ahmad Farooqi; Rossana Berardi
Journal:  Drugs Context       Date:  2022-08-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.